Skip to main content
Equibles

CSCIF · COSCIENS Biopharma Inc.

Track CSCIF — free

Use CSCIF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CSCIF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.49 At close · Oct 16
Rebalance outlook locked
Market Cap
$6.47M
Shares
997,219
Volume · Oct 16 108 Avg daily vol (3M) 994

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.49 Open$6.49 Day$6.49–6.49 52W close$0.79–7.00 Avg vol 30d1K Short int2K · 0.2% float · 1.4d Short vol98% DataJan 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$8.00M
Trailing 12 months
Net income (TTM)
$4.05M
Trailing 12 months
Revenue growth YoY
+36.1%
Year over year
Operating margin
-109.4%
Trailing 12 months
P / E (TTM)
8.2
Trailing earnings · reciprocal yield 12.2%
FCF yield
-136.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.4%
Year over year · more shares
Price change (1Y)
+152.5%
Trailing year
Short interest
0.2%
Latest settlement · 1.4 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▲67.9% $2.34M −$1.42M '24 Q2 ▼4.1% $1.87M −$5.75M '24 Q3 ▲98.8% $3.32M −$6.73M '24 Q4* ▼32.6% $1.39M −$3.65M '25 Q1 ▲17.6% $2.75M −$2.70M '25 Q2 ▼20.7% $1.48M −$1.82M '25 Q3 ▼43.4% $1.88M −$2.18M '25 Q4* LATEST ▲36.1% $1.89M $10.76M '26 Q1

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bearish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +130%
above
Price vs 50-day avg +27%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +25%
trailing
6-month return +217%
trailing
YTD return +215%
this year
Relative strength +210%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow Distributing
-88% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.17% of float · ▲ +50.2% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 1-yr low, contrarian setup
Squeeze score 45
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 230%
annualized · 1-yr
Max drawdown −82%
past year
ATR 5.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+130% Bullish
Price vs 50-day avg
+27% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow Distributing
-88% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.17% of float · ▲ +50.2% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $6 · 92% Range high $7
vs 200-day avg +130% vs 50-day avg +27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CSCIF
COSCIENS Biopharma Inc.
this stock
$6.47M +215.0% — — 0.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
0.4%
Net QoQ
-22.9K sh
Top holder
TD Waterhouse Canada Inc.
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
1.7K
Days to cover
1.4d
Change
+569 sh
View
Short Volume
Short vol %
98%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
103
Value
$686
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
98.2%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 6, 2026
This year
13
View
Exempt Offerings
Offering
$4.5M
Filed
Mar 2, 2020
View

Performance

5D 20D 120D MTD YTD
CSCIF +1.1% +25.3% +216.6% +0.6% +215.1%
SPY -2.0% +0.2% +6.7% +0.1% +11.9%
vs SPY +3.1% +25.1% +209.9% +0.5% +203.1%
Key facts CIK 1113423 CUSIP 22112H200 Visit website Investor relations